Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax(®)). We used a new anti-PS23 IgM and IgA ELISA assay, which evaluates a global response to all 23 polysaccharides contained in Pneumovax(®). Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications. This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.

Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency / Cavaliere, Filomena Monica; Milito, Cinzia; Martini, Helene; M., Schlesier; R., Drager; K., Schutz; Brunetti, Grazia; Pesce, ANNA MARIA; V., Thon; K., Warnatz; Quinti, Isabella. - In: JOURNAL OF CLINICAL IMMUNOLOGY. - ISSN 0271-9142. - STAMPA. - 33:4(2013), pp. 838-846. [10.1007/s10875-012-9856-z]

Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency

CAVALIERE, Filomena Monica;MILITO, CINZIA;MARTINI, HELENE;BRUNETTI, GRAZIA;PESCE, ANNA MARIA;QUINTI, Isabella
2013

Abstract

Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax(®)). We used a new anti-PS23 IgM and IgA ELISA assay, which evaluates a global response to all 23 polysaccharides contained in Pneumovax(®). Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications. This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.
anti-pneumococcal polysaccharide igm; elisa; anti-pneumococcal polysaccharide iga; bronchiectasis; common variable immunodeficiencies; pneumonia
01 Pubblicazione su rivista::01a Articolo in rivista
Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable Immunodeficiency / Cavaliere, Filomena Monica; Milito, Cinzia; Martini, Helene; M., Schlesier; R., Drager; K., Schutz; Brunetti, Grazia; Pesce, ANNA MARIA; V., Thon; K., Warnatz; Quinti, Isabella. - In: JOURNAL OF CLINICAL IMMUNOLOGY. - ISSN 0271-9142. - STAMPA. - 33:4(2013), pp. 838-846. [10.1007/s10875-012-9856-z]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/507142
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 27
social impact